SG11201900446QA - Crebbp related cancer therapy - Google Patents

Crebbp related cancer therapy

Info

Publication number
SG11201900446QA
SG11201900446QA SG11201900446QA SG11201900446QA SG11201900446QA SG 11201900446Q A SG11201900446Q A SG 11201900446QA SG 11201900446Q A SG11201900446Q A SG 11201900446QA SG 11201900446Q A SG11201900446Q A SG 11201900446QA SG 11201900446Q A SG11201900446Q A SG 11201900446QA
Authority
SG
Singapore
Prior art keywords
international
epizyme
massachusetts
cambridge
square
Prior art date
Application number
SG11201900446QA
Inventor
Alexandra Grassian
Scott Ribich
Jesse Smith
Darren Harvey
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of SG11201900446QA publication Critical patent/SG11201900446QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01032—Lysine N-acetyltransferase (2.3.1.32)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91051—Acyltransferases other than aminoacyltransferases (general) (2.3.1)
    • G01N2333/91057—Acyltransferases other than aminoacyltransferases (general) (2.3.1) with definite EC number (2.3.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11011110111010101111101 110 1 010110101110111101110011111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\" WO 2018/022637 Al 01 February 2018 (01.02.2018) W I P0 I P C T (51) International Patent Classification: (74) Agent: VETTER, Michael L. et al.; Choate, Hall & Ste- C12N 9/10 (2006.01) wart LLP, Two International Place, Boston, Massachusetts (21) International Application Number: 02110 (US). PCT/US2017/043757 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 25 July 2017 (25.07.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/366,249 25 July 2016 (25.07.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: EPIZYME, INC. [US/US]; 400 Technology TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Square, Cambridge, Massachusetts 02139 (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors: GRASSIAN, Alexandra; c/o Epizyme, Inc., kind of regional protection available): ARIPO (BW, GH, 400 Technology Square, 4th Floor, Cambridge, Massachu- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, setts 02139 (US). RIBICH, Scott; c/o Epizyme, Inc., 400 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Technology Square, 4th Floor, Cambridge, Massachusetts TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — 02139 (US). SMITH, Jesse; c/o Epizyme, Inc., 400 Tech-EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, nology Square, 4th Floor, Cambridge, Massachusetts 02139 — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (US). HARVEY, Darren; c/o Epizyme, Inc., 400 Technol- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ogy Square, 4th Floor, Cambridge, Massachusetts 02139 KM, ML, MR, NE, SN, TD, TG). (US). = = (54) Title: CREBBP RELATED CANCER THERAPY = — = = -0.5- = = — = — — — _ -1.5- = = = _= — 0 = ''' — 1-1 IN -3 . 5 ' M N to t f 1 0 AUTONOMIC_GANGLIA ()BREAST 0 ENDOMETRIUM O KIDNEY fa LARGE INTESTINE 0 L VER - 0 ONG 0 OESOPHAGUS 9 OVARY 0 PANCREAS 0 SKI 0 SOFT TISSUE lb STOMACH • oper ..aradigeslive_tract . t• • URINARY_TRACT 1 1 0 CENTRALNERVOUS_SYSTEM is 1 '::EE= . , 1 81 1 1 4 4''''t 1 8 1 It II It 11 n H 18 18 11 I8 11 H 11 1E 18 11 1 II iv iii Ei -,, I 1 1 1 1 11 1 1 l i ! f\"1 0 Figure 2A ,—, C::::) (57) : The present disclosure provides novel cancer therapies. The treatment of cancers harboring EP300 mutations with N CREBBP inhibition therapy is described. [Continued on next page] WO 2018/022637 Al MIDEDIMOMMIDIREEMOTHOHEIIINHINVOIS Published: — with international search report (Art. 21(3))
SG11201900446QA 2016-07-25 2017-07-25 Crebbp related cancer therapy SG11201900446QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366249P 2016-07-25 2016-07-25
PCT/US2017/043757 WO2018022637A1 (en) 2016-07-25 2017-07-25 Crebbp related cancer therapy

Publications (1)

Publication Number Publication Date
SG11201900446QA true SG11201900446QA (en) 2019-02-27

Family

ID=59521653

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900446QA SG11201900446QA (en) 2016-07-25 2017-07-25 Crebbp related cancer therapy

Country Status (12)

Country Link
US (2) US20190270797A1 (en)
EP (1) EP3487993A1 (en)
JP (2) JP2019524740A (en)
KR (1) KR20190040971A (en)
CN (1) CN109715790A (en)
AU (2) AU2017302554A1 (en)
CA (1) CA3031525A1 (en)
EA (1) EA201990370A1 (en)
IL (1) IL264277A (en)
MX (1) MX2019001001A (en)
SG (1) SG11201900446QA (en)
WO (1) WO2018022637A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012803A (en) 2013-03-15 2016-08-19 Epizyme Inc Carm1 inhibitors and uses thereof.
CN113891749A (en) 2019-03-28 2022-01-04 埃皮齐梅股份有限公司 Quinoline derivatives and their use for the treatment of cancer
KR20230028798A (en) 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 Combinations of CBP/p300 bromodomain inhibitors and KRAS inhibitors for cancer treatment
CN115701996A (en) 2020-06-25 2023-02-14 托雷莫治疗股份公司 Combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for the treatment of EGFR mutant NSCLC

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1050581A4 (en) * 1998-01-20 2005-10-19 Med & Biological Lab Co Ltd Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or accelerators of these enzymes
US8476458B2 (en) * 2007-06-21 2013-07-02 The Wistar Institute Methods and compositions for modulating P300/CBP activity
WO2011085039A2 (en) * 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
US20130195843A1 (en) * 2010-06-23 2013-08-01 British Columbia Cancer Agency Branch Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
KR20160060765A (en) * 2013-10-11 2016-05-30 제넨테크, 인크. Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
WO2016044771A1 (en) 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
WO2016044777A1 (en) 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
WO2016055028A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Therapeutic compounds and uses thereof
EP3224258B1 (en) 2014-11-27 2019-08-14 Genentech, Inc. 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors

Also Published As

Publication number Publication date
KR20190040971A (en) 2019-04-19
AU2017302554A1 (en) 2019-01-31
EA201990370A1 (en) 2019-06-28
MX2019001001A (en) 2019-10-15
US20190270797A1 (en) 2019-09-05
WO2018022637A1 (en) 2018-02-01
EP3487993A1 (en) 2019-05-29
JP2022174752A (en) 2022-11-24
AU2023254992A1 (en) 2023-11-16
CN109715790A (en) 2019-05-03
JP2019524740A (en) 2019-09-05
IL264277A (en) 2019-02-28
US20230046656A1 (en) 2023-02-16
CA3031525A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
SG11201901126UA (en) Combination therapy for cancer
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201804934PA (en) Novel Compounds
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201808125RA (en) Methods for solid tumor treatment
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201810571RA (en) Compositions comprising bacterial strains
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201804915RA (en) Methods for treating huntington's disease
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201900446QA (en) Crebbp related cancer therapy
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201811408PA (en) Adoptive cell transfer and oncolytic virus combination therapy
SG11201900361RA (en) Methods of treating prostate cancer
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201811482YA (en) Double targeted constructs to affect tumor kill
SG11201909807TA (en) Methods of manufacturing of niraparib